Molbio Diagnostics Eyes ₹940 Crore Through IPO Amidst Global Expansion

Molbio Diagnostics, a prominent player in the molecular diagnostics sector, is set to launch an initial public offering (IPO) aiming to raise ₹940 crore. The company plans to secure ₹200 crore through fresh issuance of shares to bolster its capital expenditures and enhance its operational capabilities.

Strategic Financial Moves

In addition to the fresh issuance, Molbio intends to generate ₹740 crore through an offer for sale, which will result in the promoter group's stake decreasing from 46.6% to 43%. This strategic move is part of Molbio's broader plan to strengthen its financial position and support its expansive operations across six manufacturing sites worldwide. The company currently serves over 90 countries, providing critical diagnostic solutions to government health programs, diagnostic laboratories, hospitals, and international healthcare organizations.

Revenue Growth and Market Focus

Molbio's financial performance has been robust, with revenue from operations rising by 31.5% annually to ₹1,445.7 crore between FY24 and FY26. During the same period, the company's net profit witnessed a 40.2% growth, reaching ₹164.1 crore. A significant portion of Molbio's revenue, approximately 74%, is derived from the sale of diagnostic test kits, particularly those designed for tuberculosis, which contribute to 70% of the test kit sales.

The company's flagship product, the Truenat platform, is a portable diagnostics system that delivers accurate results within an hour, catering to resource-limited settings. This innovation aligns with Molbio's focus on providing effective solutions for infectious and non-communicable diseases, with molecular testing solutions available for over 30 diseases through 43 diagnostic assays.

Market Position and Valuation

Molbio's valuation strategy is based on a price-earnings (P/E) multiple of up to 57, considering its post-IPO equity and net profit for FY26. Although the company has no directly comparable listed peers in India, it finds itself in a competitive landscape alongside other healthcare diagnostics and medical device companies such as Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre, which trade at P/E multiples between 54 and 81.

With a strong revenue base and a diversified international presence, Molbio Diagnostics presents a potential opportunity for high-risk investors seeking long-term growth. However, the concentration of revenue from major clients and the reliance on government and international aid agencies for over four-fifths of its income could pose risks.